Related Experiment Videos
In vivo models of multiple system atrophy
Pierre-Olivier Fernagut1, Imad Ghorayeb, Elsa Diguet
1Department of Neurology, University of California Los Angeles, USA.
Summary
Researchers developed new animal models for Multiple System Atrophy (MSA) to study its cause and find treatments. These models mimic striatonigral degeneration, crucial for understanding levodopa-unresponsive parkinsonism in MSA.
Area of Science:
- Neuroscience
- Neurology
- Pharmacology
Background:
- Multiple system atrophy (MSA) is a rare neurodegenerative disease with unknown causes, presenting with parkinsonian, pyramidal, and cerebellar symptoms.
- Levodopa-unresponsive parkinsonism, a key feature in 80% of MSA cases (MSA-P), is linked to degeneration in the substantia nigra and striatum.
- Limited understanding of MSA pathophysiology and treatment options necessitates the development of effective preclinical models.
Purpose of the Study:
- To create and evaluate lesion models that replicate striatonigral degeneration, the pathological hallmark of MSA-P.
- To investigate the utility of different neurotoxins and species (rats, mice, primates) for modeling MSA.
- To establish a foundation for exploring neuroprotective, neurorestorative, and symptomatic therapies for MSA.
Main Methods:
- Developed rat models using stereotaxic strategies with single or double neurotoxin-induced lesions targeting the substantia nigra and striatum.
- Utilized systemic models in mice and primates with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3-nitropropionic acid (3-NP).
- Assessed motor impairment, levodopa responsiveness, and lesion formation across different species and intoxication paradigms.
Main Results:
- Double-lesioned rats exhibited severe motor deficits, effectively mimicking various disease stages compared to single-lesioned models.
- In mice, simultaneous nigral and striatal insults exacerbated damage, while sequential MPTP treatment altered 3-NP sensitivity.
- MPTP-treated monkeys showed worsened parkinsonism and lost levodopa responsiveness following 3-NP-induced striatal lesions and dystonia.
Conclusions:
- The developed rat, mouse, and primate models accurately reproduce key pathological and clinical features of MSA-P, particularly striatonigral degeneration.
- These models provide valuable tools for investigating the functional neurobiology of the substantia nigra and striatum in MSA.
- The models are instrumental for testing novel therapeutic strategies, including neuroprotection, neurorestoration, and symptomatic treatments for MSA.